APOE and Alzheimer disease: Furthermore, human ApoE4 carriers with AD also exhibit a thinner basement membrane, increased fibrin extravasion, and pericyte loss in the blood-brain barrier compared to ApoE3-KI carriers with AD or non-AD controls [75, 76].